Difference between revisions of "Sargramostim (Leukine)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | ''Note: sargramostim does not have a known direct antineoplastic effect. However, it has been used as an adjunct for immunotherapy trials.'' | ||
| + | *[[Neuroblastoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 22: | Line 26: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Granulocyte macrophage colony-stimulating factors]] | [[Category:Granulocyte macrophage colony-stimulating factors]] | ||
| + | |||
| + | [[Category:Neuroblastoma medications]] | ||
[[Category:FDA approved in 1991]] | [[Category:FDA approved in 1991]] | ||
Revision as of 14:43, 23 August 2018
General information
Class/mechanism: Recombinant human granulocyte macrophage colony stimulating factor (GM-CSF), hematopoietic growth factor. Sargramostim binds to cell surface receptors and stimulates survival, proliferation, and differentiation of hematopoietic progenitor cells. In addition to triggering the proliferation of neutrophils, monocytes/macrophages, and myeloid-derived dendritic cells, GM-CSF has also been observed to activate mature granulocytes and macrophages.[1][2][3]
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Note: sargramostim does not have a known direct antineoplastic effect. However, it has been used as an adjunct for immunotherapy trials.
Patient drug information
- Sargramostim (Leukine/GM-CSF) package insert[1]
- Sargramostim (Leukine/GM-CSF) patient drug information (Chemocare)[4]
- Sargramostim (Leukine/GM-CSF) patient drug information (UpToDate)[5]
Also known as
- Generic names: GMCSF, GM-CSF, granulocyte macrophage colony stimulating factor
- Brand name: Leukine